H3N2 News and Research RSS Feed - H3N2 News and Research

Influenza A virus subtype H3N2 (also H3N2) is a subtype of viruses that cause influenza (flu). H3N2 viruses can infect birds and mammals. In birds, humans, and pigs, the virus has mutated into many strains. H3N2 is increasingly abundant in seasonal influenza, which kills an estimated 36,000 people in the United States each year.
CDC report reveals that younger age group is mostly hit by flu this season

CDC report reveals that younger age group is mostly hit by flu this season

This influenza season was particularly hard on younger- and middle-age adults, the Centers for Disease Control and Prevention reported in today's Morbidity and Mortality Weekly Report. [More]
Researchers show for first time how influenza A viruses infect respiratory cells

Researchers show for first time how influenza A viruses infect respiratory cells

Researchers at the University of California, San Diego School of Medicine have shown for the first time how influenza A viruses snip through a protective mucus net to both infect respiratory cells and later cut their way out to infect other cells. [More]
European Medicines Agency awards orphan drug designation to NanoViricides' DengueCide

European Medicines Agency awards orphan drug designation to NanoViricides' DengueCide

NanoViricides, Inc. announced today that the European Medicines Agency, has awarded orphan drug designation to DengueCide, the Company's drug candidate for the treatment of dengue and dengue hemorrhagic fever. [More]
Scientists highlight novel way to develop universal influenza vaccine that can protect against multiple flu strains

Scientists highlight novel way to develop universal influenza vaccine that can protect against multiple flu strains

A study led by St. Jude Children's Research Hospital scientists highlights a new approach for developing a universal influenza vaccine that could protect against multiple flu strains, including deadly pandemic strains. The research appears today in the advance online edition of the scientific journal Nature Immunology. [More]
Emerging H7N9 virus has potential to cause a pandemic

Emerging H7N9 virus has potential to cause a pandemic

A new study has found that a novel avian-origin H7N9 influenza A virus, which has recently emerged in humans, attaches moderately or abundantly to the epithelium of both the upper and lower respiratory tracts. [More]
Novartis starts shipment of 2013-2014 seasonal influenza vaccines to US customers

Novartis starts shipment of 2013-2014 seasonal influenza vaccines to US customers

Novartis announced today that it has begun shipment of its seasonal influenza vaccines to customers in the US market for the 2013-2014 season. Novartis plans to ship a minimum of 30 million doses of its influenza vaccines to the US market, including Fluvirin (Influenza Virus Vaccine), approved for use in people 4 years of age and older, and Flucelvax (Influenza Virus Vaccine), approved for use in adults 18 years of age and older. [More]
NanoViricides, LRRI sign NDA for IND-enabling efficacy studies on FluCide drug candidates

NanoViricides, LRRI sign NDA for IND-enabling efficacy studies on FluCide drug candidates

NanoViricides, Inc. said it has signed a non-disclosure agreement with the Lovelace Respiratory Research Institute. The Company intends to enter into a Master Services Agreement with LRRI for the IND-enabling efficacy studies of both its broad-spectrum injectable and oral FluCide drug candidates. [More]
First lots of 2013-2014 seasonal influenza vaccine released for U.S. distribution

First lots of 2013-2014 seasonal influenza vaccine released for U.S. distribution

Sanofi Pasteur, the vaccines division of Sanofi, announced today that the first lots of Fluzone (Influenza Virus Vaccine) for the 2013-2014 season have been released by the U.S. Food and Drug Administration for U.S. distribution and were shipped July 24. [More]
Seattle researchers map critical molecules that regulate inflammation during flu infection

Seattle researchers map critical molecules that regulate inflammation during flu infection

The influenza virus' ability to mutate quickly has produced new, emerging strains that make drug discovery more critical than ever. For the first time, researchers at Seattle BioMed, along with collaborators at the University of California, San Diego School of Medicine, St. Jude Children's Research Hospital and the University of Washington, have mapped how critical molecules regulate both the induction and resolution of inflammation during flu infection. [More]
NanoViricides submits letter of intent to file Orphan Drug Application with EMA for DengueCide

NanoViricides submits letter of intent to file Orphan Drug Application with EMA for DengueCide

NanoViricides, Inc. announced today that it has submitted its letter of intent to file an Orphan Drug Application with the European Medicines Agency for DengueCide, its drug candidate for the treatment of dengue and dengue hemorrhagic fever. [More]
NanoViricides files Orphan Drug application with FDA for DengueCide

NanoViricides files Orphan Drug application with FDA for DengueCide

NanoViricides, Inc. announced today that it has filed an Orphan Drug application with the Office of Orphan Product Development of the US FDA for DengueCide, its drug candidate for the treatment of dengue and dengue hemorrhagic fever. [More]

iBio announces production of vaccine candidate for new H7N9 influenza virus

iBio, Inc. today announced the production of a vaccine candidate for the newly emerged H7N9 influenza virus by an independent third party laboratory using the iBioLaunch platform. [More]

New MIT study reveals that H3N2 strains could pose a risk to humans

In the summer of 1968, a new strain of influenza appeared in Hong Kong. This strain, known as H3N2, spread around the globe and eventually killed an estimated 1 million people. [More]
SynCon universal H1N1 influenza vaccine generates protective antibody levels in phase 1 study

SynCon universal H1N1 influenza vaccine generates protective antibody levels in phase 1 study

Inovio Pharmaceuticals, Inc. announced today that its SynCon universal H1N1 influenza vaccine generated protective antibody levels comparable to a current FDA-approved seasonal influenza vaccine against a currently circulating influenza strain. [More]

New assays are effective in managing patients with influenza virus infection

Over 40,000 people die each year in the United States from influenza-related diseases. In patients whose immune systems are compromised, antiviral therapy may be life-saving, but it needs to be initiated quickly. It is therefore crucial to diagnose and type the influenza rapidly. [More]

Anti-inflammatory drug naproxen may exhibit antiviral activity against influenza A virus

The over-the-counter anti-inflammatory drug naproxen may also exhibit antiviral activity against influenza A virus, according to a team of French scientists. The finding, the result of a structure-based investigation, is published online ahead of print in the journal Antimicrobial Agents and Chemotherapy. [More]
UCLA researchers predict hotspots for future outbreaks of influenza virus

UCLA researchers predict hotspots for future outbreaks of influenza virus

This year's unusually long and rocky flu season would be nothing compared to the pandemic that could occur if bird flu became highly contagious among humans, which is why UCLA researchers and their colleagues are creating new ways to predict where an outbreak could emerge. [More]

Researchers identify new function for matriptase enzyme

Dr. Martin Richter (pharmacology), investigator with the Centre de recherche clinique √Čtienne-Le Bel (CRCELB) at the Centre hospitalier universitaire de Sherbrooke (CHUS) and professor in the Faculty of Medicine and Health Sciences of the Universit√© de Sherbrooke (UdeS), and his collaborators have identified a new function of the enzyme matriptase, present in the human respiratory system, that can activate a viral protein involved in infections caused by the H1N1 influenza (or flu) virus. [More]

FluGen's REDEE FLU vaccine protects against both H5N1 and H3N2 strains

Deadly flu viruses, including the H5N1 bird flu and H3N2 swine flu, may have met their match in FluGen's universal vaccine, REDEE FLU. [More]

Loyola Flu Central now available on LUHS web site

Loyola Flu Central, a weekly snapshot of flu activity locally, regionally and nationally is now available on the Loyola University Health System web site, through Twitter and on Facebook. [More]